SEC Form 4 · accession 0001193125-26-301092
AN2 Therapeutics, Inc. · ANTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua M Eizen
Officer — See Remarks
Period of report
Jul 8, 2026
Accepted (ET)
Jul 10, 2026 · 6:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001880438
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jul 8, 2026 | S | 5,945 | $4.172 | D | 206,554 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on July 1, 2026.
- F2Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date.
- F3Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2026.
Remarks
Chief Operating Officer and Chief Legal Officer